Related Content
June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to reduce ...
June 03, 2014
January 22, 2014 — The U.S. Food and Drug Administration (FDA)’s Cardiovascular and Renal Drugs Advisory Committee ...
January 22, 2014
July 25, 2013 — Merck announced that the New Drug Application (NDA) for its investigational anti-thrombotic medicine ...
July 25, 2013
May 16, 2013 — Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug ...
May 16, 2013March 25, 2013 — The largest randomized study of the vitamin niacin in patients with occlusive arterial disease has ...
March 25, 2013November 18, 2010 – In the trial of 1,623 patients with coronary heart disease (CHD) or CHD risk equivalents, an ...
November 18, 2010May 4, 2010 – A deal has been struck to produce a generic version of Merck & Company’s Zetia (ezetimibe). In the United ...
May 04, 2010
March 19, 2010 – An experimental factor Xa inhibitor given to patients with non-valvular atrial fibrillation (AF) or ...
March 19, 2010November 18, 2009 – Patient enrollment was recently completed in the TRA 2 P-TIMI 50 clinical trial to study SCH 530348 ...
November 20, 2009July 10, 2009 – Merck & Co. Inc. and Portola Pharmaceuticals Inc. this week signed an exclusive global collaboration and ...
July 10, 2009© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now